33 results
8-K
EX-10.1
BTAX
Biostax Corp.
12 Oct 22
Entry into a Material Definitive Agreement
8:49am
TO THE PRODUCT. LICENSOR SHALL HAVE NO LIABILITY WHATSOEVER TO LICENSEE OR ANY OTHER PERSON FOR OR ON ACCOUNT OF ANY INJURY, LOSS, OR DAMAGE, OF ANY KIND
8-K
EX-10.1
BTAX
Biostax Corp.
22 Jul 22
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer
3:44pm
and all claims for slander, libel, defamation, negligent or intentional infliction of emotional distress, personal injury, prima facie tort … , negligence, compensatory or punitive damages, or any other claim for damages or injury of any kind whatsoever; and
(v) any and all claims for monetary
8-K
EX-99.1
BTAX
Biostax Corp.
22 Oct 20
Immune Therapeutics, Inc. Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs
4:33pm
of significant unmet medical needs including acute radiation injury, oncology, infectious disease, inflammation and autoimmune-mediated conditions
8-K
EX-10.1
v2nyc6zry2zs
25 Sep 19
Entry into a Material Definitive Agreement
5:05pm
8-K
EX-10.1
nruhf 0xvunh2yqd7gh
11 Jun 18
Entry into a Material Definitive Agreement
12:00am
S-1
b8023kxuz6ttzdz
14 Oct 16
IPO registration
12:00am
DRS/A
h8wjo
14 Oct 16
Draft registration statement (amended)
12:00am
10-K
1uisaaqry77qj7mr9yz5
31 Mar 14
Annual report
12:00am